Related Experiment Video

Updated: Mar 13, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?

Zengliu Su1

  • 1Vanderbilt-Ingram Cancer Center, Department of Medicine/Division of Hematology-Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Thoracic Cancer
|February 1, 2011
PubMed

Insights

Epidermal growth factor receptor (EGFR) mutations impact lung cancer drug efficacy. This review covers EGFR mutation profiles in East Asian patients and strategies to overcome acquired resistance, particularly the T790M mutation.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) kinase domain mutations (exons 18-21) influence the effectiveness of EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib.
  • Non-small cell lung cancer (NSCLC) patients with sensitive EGFR mutations initially respond to TKIs but often develop acquired resistance within a year.
  • Understanding EGFR mutation profiles is crucial for tailoring NSCLC treatment strategies, especially in East Asian populations.

Approach:

  • This review synthesizes recent publications on EGFR gene mutation profiles in East Asian NSCLC patients.
  • It examines the mechanisms of acquired resistance to EGFR TKIs.
  • The review also discusses therapeutic strategies to overcome resistance, focusing on the EGFR T790M mutation.

Key Points:

  • EGFR mutations in exons 18-21 are key determinants of TKI response in NSCLC.
  • Acquired resistance, often involving the T790M mutation, limits long-term TKI efficacy.
  • EGFR mutation profiling in East Asian NSCLC patients reveals specific patterns relevant to treatment.

Conclusions:

  • EGFR mutation status is critical for predicting response and resistance to TKIs in NSCLC.
  • The T790M mutation represents a significant challenge in NSCLC treatment, necessitating targeted therapeutic approaches.
  • Further research into EGFR mutation profiles and resistance mechanisms can guide the development of more effective NSCLC therapies.
Keywords:
Acquired resistanceEGFRgene mutationlung cancertyrosine kinase inhibitors

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.4K